top of page

Third Harmonic Bio is nearing an IND submission to put a new oral KIT inhibitor into the clinic

CEO Natalie Holles describes how learnings from a setback from the company's first asset have resulted in a new program that she believes can have wide utility in multiple mast cell mediated inflammatory conditions.



Commentaires


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page